Michael A Levine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7198722/publications.pdf

Version: 2024-02-01

246 papers

14,323 citations

68 h-index 24915 109 g-index

252 all docs 252 docs citations

times ranked

252

10665 citing authors

#	Article	IF	CITATIONS
1	Hypocalcemia as the Initial Presentation of Type 2 Bartter Syndrome: A Family Report. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1679-e1688.	1.8	2
2	Novel <i>PTH</i> Gene Mutations Causing Isolated Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2449-e2458.	1.8	2
3	Longitudinal assessment of vascular calcification in generalized arterial calcification of infancy. Pediatric Radiology, 2022, 52, 2329-2341.	1.1	2
4	Mutation update: Variants of the <i>ENPP1</i> gene in pathologic calcification, hypophosphatemic rickets, and cutaneous hypopigmentation with punctate keratoderma. Human Mutation, 2022, 43, 1183-1200.	1.1	4
5	ENPP1 variants in patients with GACI and PXE expand the clinical and genetic heterogeneity of heritable disorders of ectopic calcification. PLoS Genetics, 2022, 18, e1010192.	1.5	13
6	Prospective phenotyping of long-term survivors of generalized arterial calcification of infancy (GACI). Genetics in Medicine, 2021, 23, 396-407.	1.1	44
7	Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e485-e495.	1.8	13
8	Disorders of Mineral Metabolism II. Abnormalities of Mineral Homeostasis in the Newborn, Infant, Child, and Adolescent., 2021,, 705-813.		4
9	Receptor Transduction Pathways Mediating Hormone Action. , 2021, , 30-85.		1
10	Vitamin D Metabolism or Action. , 2021, , 335-372.		0
11	Parenteral iron therapy and phosphorus homeostasis: A review. American Journal of Hematology, 2021, 96, 606-616.	2.0	16
12	A painting of the Christ Child with bowed legs: Rickets in the Renaissance. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2021, 187, 216-218.	0.7	2
13	Mild Idiopathic Infantile Hypercalcemia—Part 2: A Longitudinal Observational Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2938-2948.	1.8	6
14	High-throughput Molecular Analysis of Pseudohypoparathyroidism 1b Patients Reveals Novel Genetic and Epigenetic Defects. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4603-e4620.	1.8	12
15	Mild Idiopathic Infantile Hypercalcemiaâ€"Part 1: Biochemical and Genetic Findings. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2915-2937.	1.8	8
16	The PARADIGHM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. BMC Endocrine Disorders, 2021, 21, 232.	0.9	3
17	An Update on Vitamin D Deficiency in the twenty-first century. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, Publish Ahead of Print, .	1.2	7
18	Vitamin D Therapy and the Era of Precision Medicine. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e891-e893.	1.8	1

#	Article	IF	CITATIONS
19	Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomaliesâ€"expert opinion consensus. Pediatric Blood and Cancer, 2020, 67, e28036.	0.8	50
20	Single Gland, Ectopic Location: Adenomas are Common Causes of Primary Hyperparathyroidism in Children and Adolescents. World Journal of Surgery, 2020, 44, 1518-1525.	0.8	16
21	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. Hormone Research in Paediatrics, 2020, 93, 182-196.	0.8	42
22	Short Stature is Progressive in Patients with Heterozygous NPR2 Mutations. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3190-3202.	1.8	15
23	Differentiation of PTH-Expressing Cells From Human Pluripotent Stem Cells. Endocrinology, 2020, 161, .	1.4	11
24	SAT-399 Baseline Characteristics from the Observational PARADIGHM Registry of Patients with Chronic Hypoparathyroidism. Journal of the Endocrine Society, 2020, 4, .	0.1	0
25	Diagnosis and Management of Vitamin D Dependent Rickets. Frontiers in Pediatrics, 2020, 8, 315.	0.9	39
26	Differential Frequency of <i>CYP2R1</i> Variants Across Populations Reveals Pathway Selection for Vitamin D Homeostasis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1302-1315.	1.8	5
27	Long-acting Growth Hormone Therapy: A REAL3 Alternative to Daily Growth Hormone Treatment?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1921-e1924.	1.8	1
28	Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2392-2400.	1.8	18
29	Response of the ENPP1-Deficient Skeletal Phenotype to Oral Phosphate Supplementation and/or Enzyme Replacement Therapy: Comparative Studies in Humans and Mice. Journal of Bone and Mineral Research, 2020, 36, 942-955.	3.1	15
30	Recombinant human parathyroid hormone (1–84) is effective in CASR-associated hypoparathyroidism. European Journal of Endocrinology, 2020, 183, K13-K21.	1.9	6
31	Neonatal severe hyperparathyroidism due to a homozygous mutation of calcium-sensing receptor; a challenging case. Ceylon Medical Journal, 2020, 64, 155.	0.1	4
32	Hypoparathyroidism in Children. , 2020, , 79-97.		0
33	MON-074 Ketotic Hypercalcemia; A Possible Side Effect of Managing Refractory Epilepsy with Ketogenic Diet. Journal of the Endocrine Society, 2020, 4, .	0.1	0
34	Intragenic Deletions of GNAS in Pseudohypoparathyroidism Type 1A Identify a New Region Affecting Methylation of Exon A/B. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3197-e3206.	1.8	6
35	Hypoparathyroidism in pediatric patients. , 2020, , 93-106.		0
36	ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nature Medicine, 2019, 25, 1116-1122.	15.2	136

#	Article	IF	Citations
37	Response to Letter to the Editor: "Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia― Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5100-5101.	1.8	2
38	Bones and Joints: The Effects of Cannabinoids on the Skeleton. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4683-4694.	1.8	17
39	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5136-5147.	1.8	46
40	Response to: Obesity and Vitamin D Metabolism Modifications. Journal of Bone and Mineral Research, 2019, 34, 1384-1384.	3.1	0
41	Burosumab treatment of children with X-linked hypophosphataemic rickets. Lancet, The, 2019, 393, 2364-2366.	6.3	9
42	Inherited non-alcoholic fatty liver disease and dyslipidemia due to monoallelic ABHD5 mutations. Journal of Hepatology, 2019, 71, 366-370.	1.8	41
43	Obesity Decreases Hepatic 25-Hydroxylase Activity Causing Low Serum 25-Hydroxyvitamin D. Journal of Bone and Mineral Research, 2019, 34, 1068-1073.	3.1	100
44	Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6 Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of GACI. Journal of Investigative Dermatology, 2019, 139, 360-368.	0.3	46
45	Pitfalls with Vitamin D Research in Musculoskeletal Disorders and Recommendations on How to Avoid Them. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2019, 11, 220-226.	0.4	4
46	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 722-731.	1.8	59
47	Proteasome inhibitor bortezomib is a novel therapeutic agent for focal radiationâ€induced osteoporosis. FASEB Journal, 2018, 32, 52-62.	0.2	26
48	Heterozygous Mutations in TBX1 as a Cause of Isolated Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4023-4032.	1.8	15
49	Pseudohypoparathyroidism. Endocrinology and Metabolism Clinics of North America, 2018, 47, 865-888.	1.2	59
50	Genetic Disorders of Parathyroid Development and Function. Endocrinology and Metabolism Clinics of North America, 2018, 47, 809-823.	1.2	29
51	The Coming of Age of Hypoparathyroidism: Novel Insights into Causation, Innovative Options for Management. Endocrinology and Metabolism Clinics of North America, 2018, 47, xv-xvi.	1.2	0
52	Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3124-3130.	1.8	12
53	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nature Reviews Endocrinology, 2018, 14, 476-500.	4.3	224
54	Decreased Serum 25-Hydroxyvitamin D in Aging Male Mice Is Associated With Reduced Hepatic Cyp2r1 Abundance. Endocrinology, 2018, 159, 3083-3089.	1.4	17

#	Article	IF	CITATIONS
55	Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E446-E453.	1.8	6
56	The Role of Genetic Variation in CYP2R1, the Principal Vitamin D 25-Hydroxylase, in Vitamin D Homeostasis. , 2018, , 303-315.		2
57	Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. Human Molecular Genetics, 2018, 27, 3233-3245.	1.4	73
58	CYP3A4 mutation causes vitamin D–dependent rickets type 3. Journal of Clinical Investigation, 2018, 128, 1913-1918.	3.9	77
59	Etidronate prevents, but does not reverse, ectopic mineralization in a mouse model of pseudoxanthoma elasticum (<i>Abcc6â²/â²</i>). Oncotarget, 2018, 9, 30721-30730.	0.8	26
60	Outcomes of minimally invasive parathyroidectomy in pediatric patients with primary hyperparathyroidism owing to parathyroid adenoma: A single institution experience. Journal of Pediatric Surgery, 2017, 52, 188-191.	0.8	19
61	Digenic Inheritance of PROKR2 and WDR11 Mutations in Pituitary Stalk Interruption Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2501-2507.	1.8	36
62	Compound heterozygous mutations in <i>COL1A1</i> associated with an atypical form of type I osteogenesis imperfecta. American Journal of Medical Genetics, Part A, 2017, 173, 1907-1912.	0.7	9
63	Exome Sequencing Reveals Mutations in AIRE as a Cause of Isolated Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1726-1733.	1.8	35
64	Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c. Bone, 2017, 97, 15-19.	1.4	30
65	Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3111-3123.	1.8	170
66	CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1440-1446.	1.8	72
67	CYP2R1 mutations causing vitamin D-deficiency rickets. Journal of Steroid Biochemistry and Molecular Biology, 2017, 173, 333-336.	1.2	52
68	Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms. Journal of Bone and Mineral Research, 2017, 32, 360-372.	3.1	88
69	Low bone mineral density is a common finding in patients with homocystinuria. Molecular Genetics and Metabolism, 2016, 117, 351-354.	0.5	22
70	Association of Mutations in SLC12A1 Encoding the NKCC2 Cotransporter With Neonatal Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2196-2200.	1.8	25
71	Resting Energy Expenditure Is Decreased in Pseudohypoparathyroidism Type 1A. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 880-888.	1.8	41
72	Mendelian randomization analysis demonstrates that low vitamin D is unlikely causative for pediatric asthma. Journal of Allergy and Clinical Immunology, 2016, 138, 1747-1749.e4.	1.5	28

#	Article	IF	CITATIONS
73	The etiology and significance of fractures in infants and young children: a critical multidisciplinary review. Pediatric Radiology, 2016, 46, 591-600.	1.1	52
74	Epidemiology and Diagnosis of Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2284-2299.	1.8	230
75	Dual Effects of Bisphosphonates onÂEctopicÂSkin and Vascular Soft TissueÂMineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy. Journal of Investigative Dermatology, 2016, 136, 275-283.	0.3	40
76	A comprehensive study of long-term skeletal changes after spinal cord injury in adult rats. Bone Research, 2015, 3, 15028.	5.4	22
77	Teriparatide as a Systemic Treatment for Lower Extremity Nonunion Fractures: A Case Series. Endocrine Practice, 2015, 21, 136-142.	1.1	18
78	<i>CYP2R1</i> Mutations Impair Generation of 25-hydroxyvitamin D and Cause an Atypical Form of Vitamin D Deficiency. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1005-E1013.	1.8	94
79	Pathological calcification and the mystery of Lot's wife. Cell Cycle, 2015, 14, 3354-3355.	1.3	1
80	Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4163-4171.	1.8	57
81	The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the <i>ABCC6</i> gene. Cell Cycle, 2015, 14, 1082-1089.	1.3	57
82	25-Hydroxyvitamin D Can Interfere With a Common Assay for 1,25-Dihydroxyvitamin D in Vitamin D Intoxication. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2883-2889.	1.8	16
83	Molecular and Clinical Aspects of Pseudohypoparathyroidism. , 2015, , 781-805.		2
84	Primary Hyperparathyroidism in Children and Adolescents. , 2015, , 389-399.		2
85	Exome sequencing reveals a nonsense mutation in MMP13 as a new cause of autosomal recessive metaphyseal anadysplasia. European Journal of Human Genetics, 2015, 23, 264-266.	1.4	13
86	Autosomal Dominant Hypoparathyroidism Caused by Germline Mutation in <i>GNA11</i> Phenotypic and Molecular Characterization. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1774-E1783.	1.8	79
87	A Meta-Analysis Comparing the Biochemistry of Primary Hyperparathyroidism in Youths to the Biochemistry of Primary Hyperparathyroidism in Adults. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4555-4564.	1.8	35
88	Receptor transduction pathways mediating hormone action., 2014,, 34-89.e2.		4
89	Generation of mice encoding a conditional null allele of Gcm2. Transgenic Research, 2014, 23, 631-641.	1.3	13
90	Mutations in the ABCC6 Gene as a Cause of Generalized Arterial Calcification of Infancy: Genotypic Overlap with Pseudoxanthoma Elasticum. Journal of Investigative Dermatology, 2014, 134, 658-665.	0.3	70

#	Article	IF	Citations
91	National Health and Nutrition Examination Survey Whole-Body Dual-Energy X-Ray Absorptiometry Reference Data for GE Lunar Systems. Journal of Clinical Densitometry, 2014, 17, 344-377.	0.5	83
92	Mutations in SLC34A3/NPT2c Are Associated with Kidney Stones and Nephrocalcinosis. Journal of the American Society of Nephrology: JASN, 2014, 25, 2366-2375.	3.0	124
93	Ketotic Hypercalcemia: A Case Series and Description of a Novel Entity. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1531-1536.	1.8	14
94	Evaluating Children With Fractures for Child Physical Abuse. Pediatrics, 2014, 133, e477-e489.	1.0	232
95	Cinacalcet Monotherapy in Neonatal Severe Hyperparathyroidism: A Case Study and Review. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 7-11.	1.8	71
96	Vitamin D Metabolism or Action. , 2013, , 1-28.		0
97	Hypocalcemia in the Critically III patient. Journal of Intensive Care Medicine, 2013, 28, 166-177.	1.3	134
98	Determination of Reference Intervals for Serum Total Calcium in the Vitamin D-Replete Pediatric Population. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1946-E1950.	1.8	17
99	An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 443-451.	1.2	94
100	A novel mutation in the GCM2 gene causing severe congenital isolated hypoparathyroidism. Journal of Pediatric Endocrinology and Metabolism, 2012, 25, 741-6.	0.4	14
101	Mapping Structural Determinants within Third Intracellular Loop That Direct Signaling Specificity of Type 1 Corticotropin-releasing Hormone Receptor. Journal of Biological Chemistry, 2012, 287, 8974-8985.	1.6	14
102	Cloning and characterization of the human SH3BP2 promoter. Biochemical and Biophysical Research Communications, 2012, 425, 25-32.	1.0	5
103	A multinational study to develop universal standardization of whole-body bone density and composition using GE Healthcare Lunar and Hologic DXA systems. Journal of Bone and Mineral Research, 2012, 27, 2208-2216.	3.1	150
104	Primary hyperparathyroidism in children and adolescents. Journal of the Chinese Medical Association, 2012, 75, 425-434.	0.6	89
105	The role of SH3BP2 in the pathophysiology of cherubism. Orphanet Journal of Rare Diseases, 2012, 7, S5.	1.2	77
106	Cherubism: best clinical practice. Orphanet Journal of Rare Diseases, 2012, 7, S6.	1.2	138
107	Assessing bone health in children and adolescents. Indian Journal of Endocrinology and Metabolism, 2012, 16, 205.	0.2	46
108	Acute Diaphragmatic Rupture in a Patient with Ehlers-Danlos Syndrome. Journal of Emergency Medicine, 2011, 41, 366-368.	0.3	12

#	Article	IF	CITATIONS
109	Heterotopic Ossifications in a Mouse Model of Albright Hereditary Osteodystrophy. PLoS ONE, 2011, 6, e21755.	1.1	34
110	Three Novel Mutations in the PHEX Gene in Chinese Subjects with Hypophosphatemic Rickets Extends Genotypic Variability. Calcified Tissue International, 2011, 88, 370-377.	1.5	11
111	Decreased SH3BP2 inhibits osteoclast differentiation and function. Journal of Orthopaedic Research, 2011, 29, 1521-1527.	1.2	4
112	Madelung-Like Deformity in Pseudohypoparathyroidism Type 1b. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1507-E1511.	1.8	40
113	Vitamin D Status in Abused and Nonabused Children Younger Than 2 Years Old With Fractures. Pediatrics, 2011, 127, 835-841.	1.0	82
114	Hypercalcemia in children and adolescents. Current Opinion in Pediatrics, 2010, 22, 508-515.	1.0	101
115	Comparison of metabolism of vitamins D2 and D3 in children with nutritional rickets. Journal of Bone and Mineral Research, 2010, 25, 1988-1995.	3.1	48
116	<i>SH3BP2</i> mutations potentiate osteoclastogenesis via PLC \hat{I}^3 . Journal of Orthopaedic Research, 2010, 28, 1425-1430.	1.2	8
117	Bone Mineral Density in Pseudohypoparathyroidism Type 1a. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4465-4475.	1.8	38
118	Pseudohypoparathyroidism Type 1A and Morbid Obesity in Infancy. Endocrine Practice, 2009, 15, 249-253.	1.1	23
119	A Novel Loss-of-Function Mutation, Gln459Arg, of the Calcium-Sensing Receptor Gene Associated with Apparent Autosomal Recessive Inheritance of Familial Hypocalciuric Hypercalcemia. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4372-4379.	1.8	58
120	Hypophosphatemic Rickets with Hypercalciuria due to Mutation in <i>SLC34A3 </i> /I>/Type Ilc Sodium-Phosphate Cotransporter: Presentation as Hypercalciuria and Nephrolithiasis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4433-4438.	1.8	57
121	Imprinting Status of Gα _S , NESP55, and XLαs in Cell Cultures Derived from Human Embryonic Germ Cells: <i>GNAS</i> Imprinting in Human Embryonic Germ Cells. Clinical and Translational Science, 2009, 2, 355-360.	1.5	10
122	Structural domains determining signalling characteristics of the CRH-receptor type 1 variant R1 \hat{l}^2 and response to PKC phosphorylation. Cellular Signalling, 2008, 20, 40-49.	1.7	22
123	SH3BP2 is an activator of NFAT activity and osteoclastogenesis. Biochemical and Biophysical Research Communications, 2008, 371, 644-648.	1.0	37
124	Preimplantation Genetic Diagnosis for Severe Albright Hereditary Osteodystrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 901-904.	1.8	19
125	Analysis of the <i>GCM2</i> Gene in Isolated Hypoparathyroidism: A Molecular and Biochemical Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1426-1432.	1.8	44
126	Structural Determinants Critical for Localization and Signaling within the Seventh Transmembrane Domain of the Type 1 Corticotropin Releasing Hormone Receptor: Lessons from the Receptor Variant R1d. Molecular Endocrinology, 2008, 22, 2505-2519.	3.7	28

#	Article	IF	CITATIONS
127	Body Mass Index Differences in Pseudohypoparathyroidism Type 1aVersusPseudopseudohypoparathyroidism May Implicate Paternal Imprinting of Gαs in the Development of Human Obesity. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1073-1079.	1.8	181
128	SH3BP2 Is Rarely Mutated in Exon 9 in Giant Cell Lesions Outside Cherubism. Clinical Orthopaedics and Related Research, 2007, 459, 22-27.	0.7	17
129	Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil*. Critical Care Medicine, 2007, 35, 2071-2075.	0.4	112
130	Weakness and mental status change. Journal of Emergency Medicine, 2006, 30, 341-344.	0.3	2
131	Identification of a novel mutation of SH3BP2in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Human Mutation, 2006, 27, 717-718.	1.1	48
132	Identification of Signaling Molecules Mediating Corticotropin-Releasing Hormone-R1α-Mitogen-Activated Protein Kinase (MAPK) Interactions: The Critical Role of Phosphatidylinositol 3-Kinase in Regulating ERK1/2 But Not p38 MAPK Activation. Molecular Endocrinology, 2006, 20, 3179-3195.	3.7	51
133	Differential Responses of Corticotropin-Releasing Hormone Receptor Type 1 Variants to Protein Kinase C Phosphorylation. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1032-1042.	1.3	37
134	Persistent Hypercalcemia After Parathyroidectomy in an Adolescent and Effect of Treatment With Cinacalcet HCl. Clinical Chemistry, 2006, 52, 2286-2293.	1.5	15
135	Disorders of the Parathyroid Gland. , 2006, , 357-364.		2
136	Reduction in Gs?? Induces Osteogenic Differentiation in Human Mesenchymal Stem Cells. Clinical Orthopaedics and Related Research, 2005, &NA, 231-238.	0.7	46
137	A Mouse Model of Albright Hereditary Osteodystrophy Generated by Targeted Disruption of Exon 1 of the Gnas Gene. Endocrinology, 2005, 146, 4697-4709.	1.4	122
138	A Highly Sensitive Polymerase Chain Reaction Method Detects Activating Mutations of the <it>GNAS</it> Gene in Peripheral Blood Cells in McCune-Albright Syndrome or Isolated Fibrous Dysplasia. Journal of Bone and Joint Surgery - Series A, 2005, 87, 2489.	1.4	41
139	Regulation of Corticotropin-Releasing Hormone Receptor Type 1α Signaling: Structural Determinants for G Protein-Coupled Receptor Kinase-Mediated Phosphorylation and Agonist-Mediated Desensitization. Molecular Endocrinology, 2005, 19, 474-490.	3.7	68
140	Chest pain and arthritis. Journal of Emergency Medicine, 2005, 29, 91-95.	0.3	4
141	Differential Susceptibility to Hypertension Is Due to Selection during the Out-of-Africa Expansion. PLoS Genetics, 2005, 1, e82.	1.5	208
142	Genetic Causes of Hypoparathyroidism. , 2005, , 159-178.		1
143	READMISSION TO AN INTENSIVE CARE UNIT AFTER LUNG TRANSPLANTATION: EXPERIENCE OF A SINGLE CENTER. Chest, 2005, 128, 1951-7.	0.4	25
144	A HIGHLY SENSITIVE POLYMERASE CHAIN REACTION METHOD DETECTS ACTIVATING MUTATIONS OF THE GNAS GENE IN PERIPHERAL BLOOD CELLS IN MCCUNE-ALBRIGHT SYNDROME OR ISOLATED FIBROUS DYSPLASIA. Journal of Bone and Joint Surgery - Series A, 2005, 87, 2489-2494.	1.4	4

#	Article	IF	CITATIONS
145	Primary hyperparathyroidism: 7,000 years of progress Cleveland Clinic Journal of Medicine, 2005, 72, 1084-1085.	0.6	7
146	Protein Kinase A-Induced Negative Regulation of the Corticotropin-Releasing Hormone R1 $\hat{1}$ ± Receptor-Extracellularly Regulated Kinase Signal Transduction Pathway: The Critical Role of Ser301for Signaling Switch and Selectivity. Molecular Endocrinology, 2004, 18, 624-639.	3.7	48
147	Expression of GCMB by Intrathymic Parathyroid Hormone-Secreting Adenomas Indicates Their Parathyroid Cell Origin. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 8-12.	1.8	31
148	Characterization of GATA3 Mutations in the Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) Syndrome. Journal of Biological Chemistry, 2004, 279, 22624-22634.	1.6	145
149	Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7711-7715.	3.3	630
150	Perinatal calcium metabolism: physiology and pathophysiology. Seminars in Fetal and Neonatal Medicine, 2004, 9, 23-36.	2.8	102
151	The Pseudohypoparathyroidism Type 1b Locus Is Linked to a Region Including GNAS1 at 20q13.3. Journal of Bone and Mineral Research, 2003, 18, 424-433.	3.1	20
152	Genetic Basis for Resistance to Parathyroid Hormone. Hormone Research in Paediatrics, 2003, 60, 87-95.	0.8	43
153	Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?. Journal of Pediatrics, 2003, 142, 532-538.	0.9	47
154	Discordance between Genetic and Epigenetic Defects in Pseudohypoparathyroidism Type 1b Revealed by Inconsistent Loss of Maternal Imprinting at GNAS1. American Journal of Human Genetics, 2003, 73, 314-322.	2.6	46
155	A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. European Journal of Endocrinology, 2003, 148, 25-30.	1.9	55
156	Normal Mineral Homeostasis., 2003, 6, 14-33.		15
157	Growth Hormone Deficiency in Pseudohypoparathyroidism Type 1a: Another Manifestation of Multihormone Resistance. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4059-4069.	1.8	156
158	Clinical Management of Primary Hyperparathyroidism and Thresholds for Surgical Referral: A National Study Examining Concordance Between Practice Patterns and Consensus Panel Recommendations. Endocrine Practice, 2003, 9, 494-503.	1.1	25
159	Biochemical markers of bone metabolism: application to understanding bone remodeling in children and adolescents. Journal of Pediatric Endocrinology and Metabolism, 2003, 16 Suppl 3, 661-72.	0.4	2
160	Paternally Inherited Inactivating Mutations of the GNAS1 Gene in Progressive Osseous Heteroplasia. New England Journal of Medicine, 2002, 346, 99-106.	13.9	284
161	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site. Molecular Endocrinology, 2002, 16, 450-458.	3.7	73
162	Molecular Pathogenesis of Hypophosphatemic Rickets. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2467-2473.	1.8	74

#	Article	IF	CITATIONS
163	Asthma, Allergy, and Airway Hyperresponsiveness Are Not Linked to the \hat{I}^2 2-Adrenoceptor Gene. Chest, 2002, 121, 722-731.	0.4	10
164	Consensus Development for the Supplementation of Vitamin D in Childhood and Adolescence. Hormone Research in Paediatrics, 2002, 58, 39-51.	0.8	66
165	Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet, The, 2002, 359, 761-763.	6.3	198
166	Paternal imprinting of Gαs in the human thyroid as the basis of TSH resistance in pseudohypoparathyroidism type 1a. Biochemical and Biophysical Research Communications, 2002, 296, 67-72.	1.0	141
167	Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism. Journal of Bone and Mineral Research, 2002, 17, 1102-1110.	3.1	195
168	Pseudohypoparathyroidism., 2002, , 1137-1163.		9
169	Genetic Control of Parathyroid Gland Development and Molecular Insights into Hypoparathyroidism. , 2002, , 181-192.		0
170	Primary hyperparathyroidism in children and adolescents: the Johns Hopkins Children's Center experience 1984-2001. Journal of Bone and Mineral Research, 2002, 17 Suppl 2, N44-50.	3.1	21
171	FGF-23 Inhibits Renal Tubular Phosphate Transport and Is a PHEX Substrate. Biochemical and Biophysical Research Communications, 2001, 284, 977-981.	1.0	320
172	ABSENT HEMATURIA AND EXPENSIVE COMPUTERIZED TOMOGRAPHY: CASE CHARACTERISTICS OF EMERGENCY UROLITHIASIS. Journal of Urology, 2001, 165, 782-784.	0.2	39
173	The cAMP–Protein Kinase A Signal Transduction Pathway Modulates Ethanol Consumption and Sedative Effects of Ethanol. Journal of Neuroscience, 2001, 21, 5297-5303.	1.7	139
174	Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clinical Endocrinology, 2001, 54, 301-307.	1.2	26
175	Isolated growth hormone (GH) deficiency due to compound heterozygosity for two new mutations in the GH-releasing hormone receptor gene. Clinical Endocrinology, 2001, 54, 681-687.	1.2	46
176	Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. Journal of Neurochemistry, 2001, 76, 509-519.	2.1	135
177	Selective Resistance to Parathyroid Hormone Caused by a Novel Uncoupling Mutation in the Carboxyl Terminus of Gî±s. Journal of Biological Chemistry, 2001, 276, 165-171.	1.6	65
178	Pseudohypoparathyroidism., 2001,, 807-825.		16
179	Isolation and Characterization of Myostatin Complementary Deoxyribonucleic Acid Clones from Two Commercially Important Fish: Oreochromis mossambicusand Morone chrysops*. Endocrinology, 2001, 142, 1412-1418.	1.4	117
180	Three New Mutations in the Gene for the Growth Hormone (GH)-Releasing Hormone Receptor in Familial Isolated GH Deficiency Type IB1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 273-279.	1.8	92

#	Article	lF	Citations
181	Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. Journal of Clinical Investigation, 2001, 108, 1215-1220.	3.9	183
182	Signal Transduction of PTH and PTHrP. , 2001, , 117-126.		0
183	Guidelines for the Medical and Surgical Management of Primary Hyperparathyroidism., 2001,, 451-457.		O
184	Deficiency of the \hat{l} ±-Subunit of the Stimulatory G Protein and Severe Extraskeletal Ossification. Journal of Bone and Mineral Research, 2000, 15, 2074-2083.	3.1	110
185	Clinical spectrum and pathogenesis of pseudohypoparathyroidism. Reviews in Endocrine and Metabolic Disorders, 2000, 1, 265-274.	2.6	34
186	Pseudohypoparathyroidism 1b: Exclusion of Parathyroid Hormone and Its Receptors as Candidate Disease Genes1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2239-2246.	1.8	23
187	Urocortin, but Not Corticotropin-Releasing Hormone (CRH), Activates the Mitogen-Activated Protein Kinase Signal Transduction Pathway in Human Pregnant Myometrium: An Effect Mediated via $R1\hat{1}\pm$ and $R2\hat{1}^2$ CRH Receptor Subtypes and Stimulation of Gq-Proteins. Molecular Endocrinology, 2000, 14, 2076-2091.	3.7	112
188	Rapid parathyroid hormone measurement during venous localization. Clinica Chimica Acta, 2000, 295, 193-198.	0.5	17
189	The Molecular Basis for Parathyroid Hormone Resistance in Pseudohypoparathyroidism., 2000,, 179-209.		O
190	Effect of Severe Growth Hormone (GH) Deficiency due to a Mutation in the GH-Releasing Hormone Receptor on Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins, and Ternary Complex Formation Throughout Life1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4118-4126.	1.8	81
191	A Novel Spliced Variant of the Type 1 Corticotropin-Releasing Hormone Receptor with a Deletion in the Seventh Transmembrane Domain Present in the Human Pregnant Term Myometrium and Fetal Membranes. Molecular Endocrinology, 1999, 13, 2189-2202.	3.7	120
192	Familial Dwarfism due to a Novel Mutation of the Growth Hormone-Releasing Hormone Receptor Gene ¹ . Journal of Clinical Endocrinology and Metabolism, 1999, 84, 917-923.	1.8	188
193	Pancreatic Glucagon-Like Peptide-1 Receptor Couples to Multiple G Proteins and Activates Mitogen-Activated Protein Kinase Pathways in Chinese Hamster Ovary Cells*. Endocrinology, 1999, 140, 1132-1140.	1.4	182
194	Pseudohypoparathyroidism: From Bedside to Bench and Back. Journal of Bone and Mineral Research, 1999, 14, 1255-1260.	3.1	37
195	Clinical Implications of Genetic Defects in G Proteins. Archives of Medical Research, 1999, 30, 522-531.	1.5	67
196	Pseudohypoparathyroidism., 1999,, 39-58.		0
197	Coupling of the PTH/PTHrP Receptor to Multiple G-Proteins: Direct Demonstration of Receptor Activation of G _s , G _{q/11} , and G _{i(1)} by $[\hat{l}_{\pm} - (\sup)32GTP-\hat{l}_{\pm} - (\sup)32-Azidoanilide Photoaffinity Labeling. Endocrine, 1998, 8, 201-210.$	2.2	86
198	Cost implications of different surgical management strategies for primary hyperparathyroidism. Surgery, 1998, 124, 1028-1036.	1.0	36

#	Article	IF	CITATIONS
199	Molecular Diagnosis of Residual and Recurrent Thyroid Cancer by Amplification of Thyroglobulin Messenger Ribonucleic Acid in Peripheral Blood1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4435-4442.	1.8	92
200	Reproductive Dysfunction in Women with Albright's Hereditary Osteodystrophy1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 824-829.	1.8	59
201	Thresholds for Surgery and Surgical Outcomes for Patients with Primary Hyperparathyroidism: A National Survey of Endocrine Surgeons. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2658-2665.	1.8	187
202	Hypoparathyroidism and Pseudohypoparathyroidism., 1998,, 501-529.		0
203	Olfactory Dysfunction in Type I Pseudohypoparathyroidism: Dissociation from G _s α Protein Deficiency ¹ . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 247-250.	1.8	26
204	Thyroid-Specific Expression of Cholera Toxin A1 Subunit Causes Thyroid Hyperplasia and Hyperthyroidism in Transgenic Mice*. Endocrinology, 1997, 138, 3133-3140.	1.4	71
205	Targeted Disruption of Gnas in Embryonic Stem Cells*. Endocrinology, 1997, 138, 4058-4063.	1.4	16
206	Primary hyperparathyroidism. Lancet, The, 1997, 349, 1233-1238.	6.3	121
207	[24] Molecular methods for analysis of genetic polymorphisms: Application to the molecular genetic study of genes encoding \hat{l}^2 2-adrenoceptor and stimulatory G protein \hat{l}^2 2-adrenoceptor and stimulatory G protein \hat{l}^2 3-bunnit. Methods in Neurosciences, 1996, 29, 379-400.	0.5	1
208	Clinical Implications of Genetic Defects in G Proteins: The Molecular Basis of McCune-Albright Syndrome and Albright Hereditary Osteodystrophy. Medicine (United States), 1996, 75, 171-184.	0.4	144
209	Normal parathyroid hormone responsiveness of bone-derived cells from a patient with pseudohypoparathyroidism. Journal of Bone and Mineral Research, 1996, 11, 8-14.	3.1	43
210	Albright hereditary osteodystrophy and $del(2)(q37.3)$ in four unrelated individuals. American Journal of Medical Genetics Part A, 1995, 58, 1-7.	2.4	98
211	Probing the Bimolecular Interactions of Parathyroid Hormone and the Human Parathyroid Hormone/Parathyroid Hormone-Related Protein Receptor. 2. Cloning, Characterization, and Photoaffinity Labeling of the Recombinant Human Parathyroid Hormone/Parathyroid Hormone-Related Protein Receptor, Biochemistry, 1995, 34, 10553-10559.	1.2	53
212	Reduced adenylyl cyclase activation with no decrease in \hat{l}^2 -adrenergic receptors in basenji greyhound leukocytes: Relevance to \hat{l}^2 -adrenergic responses in airway smooth muscle. Journal of Allergy and Clinical Immunology, 1995, 95, 860-867.	1.5	12
213	Enhanced Expression of the Inhibitory Protein Gi2alpha and Decreased Activity of Adenylyl Cyclase in Lymphocytes of Abstinent Alcoholics. Alcoholism: Clinical and Experimental Research, 1993, 17, 315-320.	1.4	44
214	Stress alters adenylyl cyclase activity in the pituitary and frontal cortex of the rat. Life Sciences, 1993, 53, 1719-1727.	2.0	14
215	Impaired \hat{l}^2 -adrenergic Receptor Activation of Adenylyl Cyclase in Airway Smooth Muscle in the Basenji-Greyhound Dog Model of Airway Hyperresponsiveness. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 668-675.	1.4	38
216	Pseudohypoparathyroidism with osteitis fibrosa cystica: Direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. Journal of Bone and Mineral Research, 1993, 8, 83-91.	3.1	83

#	Article	IF	Citations
217	Mapping of the gene encoding the $\hat{l}\pm$ subunit of the stimulatory G protein of adenylyl cyclase (GNAS1) to 20q13.2 $\hat{a}\uparrow$ q13.3 in human by in situ hybridization. Genomics, 1991, 11, 478-479.	1.3	92
218	A Proposed Role for Chromogranin A as a Glucocorticoid-Responsive Autocrine Inhibitor of Proopiomelanocortin Secretion*. Endocrinology, 1991, 128, 1345-1351.	1.4	50
219	Hormonal Tolerance to Ethanol is Associated with Decreased Expression of the GTP-Binding Protein, Gsalpha, and Adenylyl Cyclase Activity in Ethanol-Treated LS Mice. Alcoholism: Clinical and Experimental Research, 1991, 15, 705-710.	1.4	58
220	The McCune–Albright Syndrome. New England Journal of Medicine, 1991, 325, 1738-1740.	13.9	32
221	Expression of Chromogranin-A Messenger Ribonucleic Acid in Parathyroid Tissue from Patients with Primary Hyperparathyroidism*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1668-1673.	1.8	6
222	Immunochemical Analysis of the i \hat{l} $\pm \langle i \rangle$. Subunit of the Stimulatory G-Protein of Adenylyl Cyclase in Patients with Albright's Hereditary Osteodystrophy*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 1208-1214.	1.8	59
223	Mutation in the Gene Encoding the Stimulatory G Protein of Adenylate Cyclase in Albright's Hereditary Osteodystrophy. New England Journal of Medicine, 1990, 322, 1412-1419.	13.9	396
224	Chromosomal localization of the genes encoding two forms of the G protein \hat{l}^2 polypeptide, \hat{l}^21 and \hat{l}^23 , in man. Genomics, 1990, 8, 380-386.	1.3	77
225	Inhibition of Glucose-Stimulated Insulin Release in the Perfused Rat Pancreas by Parathyroid Secretory Protein-I (Chromogranin-A)*. Endocrinology, 1989, 124, 1235-1238.	1.4	48
226	Familial Isolated Hypoparathyroidism. Medicine (United States), 1986, 65, 73-81.	0.4	77
227	Olfactory dysfunction in humans with deficient guanine nucleotide-binding protein. Nature, 1986, 322, 635-636.	13.7	75
228	Membrane Association of Soluble Protein Activators of Rat Liver Adenylate Cyclase Evidence for Distinctness from the Guanine Nucleotide-binding Stimulating Protein (NS). Endocrine Research, 1986, 12, 269-291.	0.6	1
229	Evidence for Normal Antidiuretic Responses to Endogenous and Exogenous Arginine Vasopressin in Patients with Guanine Nucleotide-Binding Stimulatory Protein-Deficient Pseudohypoparathyroidism*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 221-224.	1.8	48
230	Activity of the Stimulatory Guanine Nucleotide-Binding Protein Is Reduced in Erythrocytes from Patients with Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism: Biochemical, Endocrine, and Genetic Analysis of Albright's Hereditary Osteodystrophy in Six Kindreds*. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 497-502.	1.8	139
231	The Inhibitory Adenylate Cyclase Coupling Protein in Pseudohypoparathyroidism*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 351-354.	1.8	16
232	Clinical Implications of Guanine Nucleotide–Binding Proteins as Receptor–Effector Couplers. New England Journal of Medicine, 1985, 312, 26-33.	13.9	130
233	Infantile hypothyroidism in two sibs: An unusual presentation of pseudohypoparathyroidism type Ia. Journal of Pediatrics, 1985, 107, 919-922.	0.9	60
234	Balanced rearrangement of chromosomes 2, 5, and 13 in a family with duplication 5q and fetal loss. American Journal of Medical Genetics Part A, 1984, 19, 783-790.	2.4	15

#	Article	lF	CITATIONS
235	Resistance to multiple hormones in patients with pseudohypoparathyroidism. American Journal of Medicine, 1983, 74, 545-556.	0.6	277
236	Deficient guanine nucleotide regulatory unit activity in cultured fibroblast membranes from patients with pseudohypoparathyroidism type I. A cause of impaired synthesis of 3',5'-cyclic AMP by intact and broken cells. Journal of Clinical Investigation, 1983, 72, 316-324.	3.9	84
237	An Association between Neonatal Severe Primary Hyperparathyroidism and Familial Hypocalciuric Hypercalcemia in Three Kindreds. New England Journal of Medicine, 1982, 306, 257-264.	13.9	174
238	Familial Hypocalciuric Hypercalcemia. New England Journal of Medicine, 1982, 307, 416-426.	13.9	105
239	The Hypocalciuric or Benign Variant of Familial Hypercalcemia: Clinical and Biochemical Features in Fifteen Kindreds. Medicine (United States), 1981, 60, 397-412.	0.4	357
240	Maximal Urine-Concentrating Ability: Familial Hypocalciuric Hypercalcemia <i>Versus</i> Typical Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 736-740.	1.8	115
241	Intraoperative Measurements of Urinary Cyclic Amp to Guide Surgery for Primary Hyperparathyroidism. New England Journal of Medicine, 1980, 303, 1457-1460.	13.9	27
242	Chapter 75. Hypoparathyroidism and Pseudohypoparathyroidism., 0,, 354-361.		6
243	Thyroid-Specific Expression of Cholera Toxin A1 Subunit Causes Thyroid Hyperplasia and Hyperthyroidism in Transgenic Mice. , 0, .		20
244	Isolation and Characterization of Myostatin Complementary Deoxyribonucleic Acid Clones from Two Commercially Important Fish: Oreochromis mossambicusand Morone chrysops. , 0, .		36
245	Thresholds for Surgery and Surgical Outcomes for Patients with Primary Hyperparathyroidism: A National Survey of Endocrine Surgeons. , 0, .		59
246	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site., 0,.		22